INTRODUCTION
Drug therapies for the treatment of infection with HIV and related opportunistic infections are the primary weapons to improve the quality of life and increase the length of survival for people with HIV disease. The combination of nucleoside antiretrovirals with protease inhibitors demonstrates the greatest potential for reducing plasma HIV and increasing CD4 cell counts (Collier et al., 1996) . In fact, recent studies demonstrate that these combination drug therapies slow the progression of HIV disease and have beneficial effects lasting for as long as at least 1 year (Gulick et al., 1997) . In addition, AIDS researchers presenting at an Interscience Conference on Antimicrobial Agents and Chemotherapy in Toronto, Canada, in September, 1997, concluded that the three-drug therapy continues to fight off HIV in 79 percent of the patients treated for 2 years and that the immune system strengthens the longer the drugs work (Waldholz, 1997) .
Although there is limited information about the best time to initiate therapy, the International AIDS Society currently recommends that antiretroviral therapy be considered for all HIV-infected individuals with detectable plasma HIV ribonucleic acid (Carpenter et al., 1997) . In addition, treatment guidelines published by the Federal Government recommend a tripledrug regimen, with the preferred treatment including at least one protease inhibitor (Fauci et al., 1997) . Hence, there is a growing consensus for offering treatment at earlier stages of the disease with combinations of several drugs.
Similarly, increased knowledge and experience with treating HIV-related opportunistic illnesses resulted in the development of guidelines for the prevention of these infections by the U.S. Public Health Service and the Infectious Disease Society of America (Centers for Disease Control and Prevention, 1997b) . The incidence rates of a number of opportunistic infections among people with HIV disease have declined in recent years and are being diagnosed at a later stage of HIV disease as a result of the effective use of antiretroviral drugs, targeted preventive therapy, and more comprehensive clinical management of the disease (Moore and Chaisson, 1996) . Given the use of combination drug therapies to fight HIV infection and the use of medications to treat related opportunistic infections, the number of drugs needed by people with HIV disease can be extensive, particularly for those in later stages of the disease.
With the advent of highly active antiretroviral therapy and other medications, the clinical course of HIV disease is changing in the United States. The annual incidence of HIV-related opportunistic infections declined in 1996 for the first time (Centers for Disease Control and Prevention, 1997a) . A study of people with HIV disease who were at the greatest risk for illness or death shows a dramatic reduction in morbidity and mortality, with these reductions in disease and death linked to the increased use of combination antiretroviral therapy, and the most dramatic reductions associated with the use of protease inhibitors (Palella et al., 1998) . This study documented that mortality declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years during 1997. Similarly, the incidence of selected opportunistic infections declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years during 1997.
These trends suggest that access and adherence to HIV drug regimens, particularly combination antiretrovirals including the protease inhibitors, are increasingly important to the survival of individuals with HIV disease. However, these effective medications are expensive, with combination antiretroviral therapy including protease inhibitors costing at least $12,000 per year for each person treated (Hirschel and Francioli, 1998) . Earlier and more intensive treatment of HIV carries important implications for State and Federal programs that assist individuals in obtaining medications. As more individuals with HIV seek care, public programs are faced with a growing demand for expensive drugrelated benefits in an environment of limited public resources.
RYAN WHITE CARE ACT
The Ryan White Comprehensive AIDS Resource Emergency (CARE) Act (Public Law 101-381) was enacted in August, 1990 , to improve both the quality and availability of care for people with HIV disease and their families (U.S. Department of Health and Human Services, 1993) . The original legislation authorized: grants to metropolitan areas with the largest number of AIDS cases to help provide emergency services (Title I); grants to the States to improve the quality, availability, and organization of health and related support services (Title II); grants to State health departments for AIDS early intervention services (Title IIIa) and community-based primar y care facilities (Title III-b); and grants for research and evaluation initiatives, including demonstration programs for pediatric AIDS research (Title IV) (McKinney, et al., 1993) . Title II of the CARE Act allows States to allocate funds among any or all of four areas to cover home-based health services, provide medication and other treatments, continue private health insurance coverage, or fund HIV care consortia (Health Care Financing Administration, 1995) .
Federal appropriations for the CARE Act have increased dramatically since the law's inception. As Table 1 shows, total Federal appropriations for all CARE Act programs increased from $220.6 million in 1991 to $1.15 billion during 1998, with more than $1.3 billion requested in President Clinton's proposed budget for fiscal year 1999. For example, California contributed more than $27 million, New York contributed more than $10 million, and Louisiana $16 million during 1997, but most States contributed less than $1 million or nothing at all to their ADAP during 1997 (Health Resources and Services Administration, 1997). Of the total ADAP funding in the United States of $387.9 million from all sources during fiscal year 1997, about $220 million (57 percent) came from Title II of the CARE Act, $41 million (11 percent) came from Title I of the CARE Act, $101 million (26 percent) came from State funding, and $26 million (7 percent) came from other sources (Health Resources and Services Administration, 1997).
Although the Ryan White legislation did not establish income eligibility restrictions for people to receive CARE Act services, the law did specify that CARE Act programs must be the payer of last resort (Health Care Financing Administration, 1995) . However, CARE Act funds can be used to pay for care provided to Medicaid recipients if the State Medicaid program does not cover a needed health service or if a Medicaid recipient's need for a health (Buchanan and Smith, 1996) . The expense of the protease inhibitors, when used in combination drug therapies, will make the fiscal problems of these ADAPs even worse. The objective of this article is to identify how States are implementing ADAPs. This research presents the results of a 1997 survey that collected data on: ADAP beneficiaries, including financial and medical eligibility policies; changes in ADAP eligibility criteria; the implementation of waiting lists for ADAP coverage, with the number of people and the length of time waiting; the use of drug formularies, the number of drugs covered and a summary of how new drugs are added to the formularies; changes in the number of drugs covered by the ADAPs; and coverage of the protease inhibitors by the ADAPs in each State, as well as assessments of the impact these medications are having on the ADAPs in each State.
METHODOLOGY
This survey of the State ADAPs was part of an HIV-related project funded by a grant from HCFA. The survey questionnaire included four sections: (1) the number of people receiving benefits, with questions assessing changes in the number of people covered; (2) medical and financial eligibility policies, with questions assessing changes in financial eligibility criteria and questions relating to the implementation of waiting lists; (3) prescription drug coverage, with questions asked about the number of drugs covered, changes in the number of covered drugs, the off-label use of drugs, and how new drugs are added to the ADAP formulary; and (4) ADAP coverage of protease inhibitors and the impact this coverage is having on the ADAP in each State.
The survey began in early March 1997, with four additional mailings of the questionnaire sent to States not responding at about 6-week intervals. The questionnaires were sent to the AIDS program directors in the 50 States and the District of Columbia. The names and addresses of these program directors were initially obtained from the Health Resources and Services Administration (1995) . Through contact with these program directors, an updated mailing list for 1997 was developed that focused on ADAP administrators in each State (Buchanan and Smith, 1996) . Completed questionnaires were received from 48 States when the survey ended in late September 1997. 1 The survey responses were summarized into four tables and mailed to the ADAPs for verification, corrections, or updates in October 1997. Updates and corrections received from the ADAPs are included in the tables presented in this article. The survey process, including verification, was completed in December 1997.
ADAP BENEFICIARIES AND ELIGIBILITY POLICIES

ADAP Beneficiaries
The questionnaire asked the ADAP administrators to estimate the number of people who received drug benefits from the ADAP in their State during 1997, with the responses presented in Table 2 . The ADAPs provided prescription drug coverage to large numbers of people, especially in States with a high incidence of HIV disease. For example, the ADAP in California provided medication coverage to an estimated 20,000 people during 1997, while the program in Florida provided drug benefits to an estimated 7,000 people. The ADAP in New York provided drug coverage to more than 10,600 people, and the ADAP in Texas served more than 5,400 during 1997.
In addition, the questionnaire asked the ADAP administrators to estimate how the number of people receiving ADAP benefits in their State during 1997 compared with the number of people receiving these benefits in 1996. The ADAP administrators in almost all States estimated that the number of people receiving ADAP benefits during 1997 increased, compared with 1996, except for Illinois, Nevada, and North Dakota, where the ADAP administrators estimated that the number of people receiving benefits remained the same during 1997, compared with 1996. 2 In addition, the ADAP administrator in Alabama estimated that the number of people receiving ADAP benefits in that State decreased in 1997, and the administrator from Missouri reported that the ADAP in that State began in late 1996, thus making a comparison inappropriate.
The questionnaire also asked the ADAP administrators to estimate how the number of people expected to receive ADAP benefits during 1998 compares with the number of people receiving these benefits in 1997. The ADAP administrators in almost all States expect the number of people receiving medications from ADAPs to increase in 1998, compared with 1997, and ADAP administrators expect the number of people receiving benefits to remain the same during 1998 in Alabama, Georgia (unless additional funds are received), and South Dakota. 3 (The ADAP administrator from Missouri did not answer this question and the District of Columbia, Iowa, and Oklahoma did not respond to the survey.)
Medical Eligibility Policies
The questionnaire asked the ADAP administrators to provide medical eligibility standards for ADAP benefits in their State during 1997, (responses summarized in Table 2 ). In addition to a diagnosis of HIV infection, a number of States require a CD4 count below a certain level (for example, a CD4 count below 550 in Kentucky) or a viral load above a certain level (for example, a viral load of 30,000 copies or more in Mississippi) to meet ADAP medical eligibility criteria in their State. Many States only require documented infection with HIV. The ADAP in Oregon responded that its T-cell requirement for eligibility was dropped.
Financial Eligibility Policies
The questionnaire asked the ADAP administrators to provide the maximum gross monthly income during 1997 to be eligible for ADAP benefits for both an indi- vidual in a one-person household and an individual in a four-person household. As Table 2 shows, these 1997 financial eligibility requirements for ADAP coverage in most States allow relatively high income levels, especially when compared with Medicaid income eligibility requirements. In most States the ADAP income eligibility levels are at least twice the Federal poverty guidelines, with a number of States allowing even more generous income levels for eligibility. The ADAP in North Dakota reported no upper limit on income during 1997.
Trends in Financial Eligibility
The ADAP administrators were asked in the survey to compare financial eligibility criteria implemented in 1996 with those in place during 1997. Compared with 1996, financial eligibility criteria for the ADAPs in the majority of States remained the same. However, financial eligibility criteria did change during 1997, compared with 1996, in a number of States, as Table 2 shows. The questionnaire also asked the ADAP administrators if they expected the financial eligibility criteria implemented in their State to become more restrictive during 1998. The financial eligibility requirements for ADAP benefits in all States are expected to remain the same during 1998, except in North Carolina, Oregon, Rhode Island, and the State of Washington, where these criteria are expected to become more restrictive. 4 In response to this question, the State of Washington further explained that "we are considering requiring enrollees with income between 200 percent FPL [Federal poverty level] and 370 percent FPL to have primary insurance, and we will only pay as a secondary payer." (The ADAP in Missouri did not answer this question.)
WAITING LISTS
The questionnaire asked the ADAP administrators if their State implemented a waiting list for people waiting to receive ADAP benefits during 1997. As Table 3 documents, ADAPs in 12 States reported the use of waiting lists for ADAP benefits in 1997. In addition to these 12, the ADAP in North Carolina responded that it "will be instituting" a waiting list for program benefits, and the ADAP in Virginia had implemented a waiting list during February 1997, although no one was waiting for benefits at the time of the 1997 survey. In contrast, during 1995, ADAPs in only Alabama, Arkansas, Delaware, Indiana, and South Carolina reported the implementation of waiting lists. Oklahoma anticipated the use of waiting lists in 1995, and Nevada reported that the mechanics for a waiting list were developed in 1995, although no one was waiting for benefits at the time of the 1995 study (Buchanan and Smith, 1996) . Table 3 presents the number of people waiting for ADAP benefits in States reporting the implementation of waiting lists during 1997. The ADAP administrator in Florida responded that 850 Floridians were waiting for ADAP coverage in late 1997, with more than 100 people waiting in Alabama, Mississippi, and South Carolina. As Table 3 also illustrates, the length of wait can be long, as much as 6 months or longer in Alabama, Mississippi, Montana, and South Dakota. The South Carolina ADAP responded that "We get 100 new cases reported in South Carolina each month. We get several 100 applications [for the ADAP] each month. Right now it takes six weeks to get on the program. That can change tomorrow, based on funding."
PRESCRIPTION DRUG FORMULARIES
The ADAP administrators were asked in the survey to provide the number of medications on the ADAP drug formulary in their State during 1997. As Table 4 presents, the number of drugs on these formularies varies among the States, ranging at the time of the survey from three drugs (all protease inhibitors) in Louisiana to as many as 207 medications in New York. The questionnaire asked the ADAP administrators to explain how a new drug can be added to the ADAP formulary in their State, with their responses summarized in Table 4 . The ADAPs in most States utilize a review process administered by a council, board, committee, or advisory group. 
No-but off-label use
After an analysis of the fiscal impact, the drug is added if funds available.
is not monitored
The MIC reviews the formulary at least twice per year. 
Changes in the Number of Drugs
The questionnaire asked the ADAP administrators to compare the number of drugs on the ADAP formulary in their State during 1996 with the number of medications on this formulary in 1997. The number of drugs increased in almost all States during 1997, with decreases reported in Montana and Vermont. 5 In addition, the number of drugs on the ADAP formulary remained the same during 1997 in Arkansas, Louisiana, Maryland, Nebraska, North Dakota, Oregon, and Pennsylvania. (The District of Columbia, Iowa, and Oklahoma did not respond to the survey.)
The ADAP administrators also were asked if they expected the number of medications on the ADAP formulary in their State to change during 1998. Almost all ADAP administrators expected the number of drugs on the ADAP formulary in their State to increase during 1998, including South Carolina, which "hopes to add drugs." 6 In contrast, the ADAP administrators in New Mexico and North Dakota expected the number of drugs on their formulary to decrease in 1998. The number of drugs on the ADAP formularies is expected to remain the same during 1998 in Georgia, Nebraska, and South Dakota. ADAP administrators in Pennsylvania and Wyoming responded that at the time of the survey they were unable to determine if the number of drugs on their formularies would change in 1998. The administrators in Louisiana, Michigan, and the State of Washington responded that the number of drugs on the formulary in their States during 1998 depends on FDA approval of new medications.
Off-Label Use
A drug must be approved by the FDA as safe and effective for uses described in a New Drug Application before it can be marketed (Lasagna, 1989) . Evidence of safety and efficacy are provided by the manufacturer from investigations of the drug's effects on controlled patient populations. These investigations substantiate the use of a drug for specific indications. Although a drug may have multiple uses, the FDA only approves labeling that reflects indications for conditions that have been researched within these trials (Laetz and Silberman, 1991) .
A physician, however, may prescribe a drug approved by the FDA for other uses besides those listed in the product label. In many circumstances the standard of care for a particular condition may include a drug not labeled for that use (Nightingale, 1986) . Prescribing a drug in this manner is commonly called "off-label" or "unlabeled use," with this practice supported by such organizations as the FDA, the American Medical Association, and the American Society of Hospital Pharmacists (Food and Drug Administration, 1982; American Society of Hospital Pharmacists, 1992) . The absence of an indication within the product labeling, however, does not suggest that off-label use is experimental or inappropriate.
Many drugs used in the management of HIV or in the treatment of associated opportunistic infections are prescribed off label (Buchanan and Smith, 1994) . In fact, off-label use of medications in HIV disease is often the community standard of practice for many HIV-related conditions (Brosgart et al., 1996) . Recent FDA actions increase the importance of allowing off-label uses of drugs in HIV-related care. In response to the spread of HIV infection, the FDA changed its policies to accelerate approval of drugs for serious and life-threatening conditions, such as HIV disease, allowing access earlier in the approval process than previously permitted (Dunbar, 1991; Edgar and Rothman, 1990) . Although these policy changes expanded the number of medications available to treat HIV-related conditions, the labeling of many of these drugs has been approved with narrow indications, which can limit patient access to these drugs if ADAPs do not allow off-label use. Another reason for off-label use is that clinical expertise in the rapidly evolving field of AIDS-related care outdistances the regulatory process for approving new uses of drug therapies.
The questionnaire asked the ADAP administrators if the ADAP in their State allowed the off-label use of drugs on the ADAP formulary during 1997. The questionnaire defined off-label use as "prescribing the drug for uses other than labeled indications." As Table 4 shows, the ADAPs in many States allowed the off-label use of medications on the ADAP formulary during 1997. A number of ADAP administrators also noted, however, that the off-label use of drugs on the ADAP formulary was not monitored in their State during 1997. If the ADAPs do not monitor or enforce prohibitions on off-label use, then off-label use of covered medications may occur.
PROTEASE INHIBITORS
Coverage of the Protease Inhibitors
The questionnaire concluded with a section asking the ADAP administrators about: (1) coverage of the protease inhibitors, (2) which of these drugs were covered, and (3) the impact that coverage of these medications has had on the ADAP in their State. As Table 5 presents, almost all the ADAPs covered the four protease inhibitors approved by the FDA. However, the ADAPs in Nevada, Oregon, and South Dakota did not cover any of the protease inhibitors at the time of the sur vey. Although the Arkansas ADAP did not include protease inhibitors on its formulary at the time of the survey, these medications were provided through the HIV consortia funded by Title II of the CARE Act according to the survey response from that State.
Impact of the Protease Inhibitors
As Table 5 documents, coverage of protease inhibitors has had an impact on the Title II programs in all but 9 of the 48 States participating in the survey. As Table 6 summarizes, a shift in Title II funds from other programs to the ADAPs is the most common impact reported (by 21 States), followed by the implementation of waiting lists in 7 States. The "other" responses reported in Table 6 were a cautiousness and the development of a protocol for adding new drugs in Connecticut, a shift of State prevention funds in Illinois, studying cost containment in Indiana, a temporary limit on access to protease inhibitors in Ohio, the use of Title II supplemental funding to add coverage of the protease inhibitors in South Carolina, development of guidelines for the specific use of protease inhibitors in Tennessee, and increased copayment responsibilities required from patients in Utah. (All of these responses that are summarized as "other" in Table 6 are presented in detail in Table 5 .)
SUMMARY AND CONCLUSIONS
The various programs funded at least in part by Title II of the CARE Act strengthen the public sector safety net that provides Wyoming All protease inhibitors approved by Reduction in the number of medications on the formulary ("formulary developed to ensure the FDA are covered "that we had money for the protease inhibitors"), implementation of a waiting list for 3 months during 1996, and a cap or limit on the dollar value of medications. 5
coverage of health and care-related services to people with HIV disease. These CARE Act programs provide coverage to people with HIV who lack private health insurance or who do not qualify for Medicaid or Medicare. In this article, we have focused on the ADAPs. Financial eligibility requirements for these ADAPs are generous, allowing people with incomes too high for Medicaid eligibility to qualify for ADAP benefits. The ADAP administrators in almost all States expected these financial eligibility criteria to remain the same in their State during 1998. At the same time, the ADAP administrators in almost all States expect the number of people receiving ADAP benefits and the number of drugs on the ADAP formulary to increase during 1998. Without increased public funding for the ADAPs, the increasing number of people receiving program benefits and the increasing need for an expanding number of beneficial medications will lead to some form of rationing. This rationing could be more restrictive financial and medical eligibility criteria, a reduction in the number of covered drugs, limits on the number of medications each beneficiary may receive, the implementation of waiting lists, or some combination of these or other options. As Tables 5 and 6 illustrate, these forms of rationing are being implemented by a number of States. In addition, at least 12 States reported the implementation of waiting lists for ADAP benefits during 1997, more than double the number of States administering ADAP waiting lists in 1995. The number of people on ADAP waiting lists is increasing, along with the number of days these people must wait for prescription drug benefits to begin. Increased public spending on the programs funded by the CARE Act is necessary to provide the health services needed by people with HIV disease and maintain these important programs in the public sector safety net for HIV care.
